Log in or register to see all Alerts
New HTA Decisions in England
January 2020
Drug name
LYNPARZA® (olaparib)
Decision date
Therapeutic area
Therapeutic sub area
Ovarian cancer
Recommended (CDF)
Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults.
Decision Detail
It is recommended only if the conditions in the managed access agreement for olaparib are followed.
The clinical evidence for olaparib was presented in SOLO‑1, an ongoing double-blind randomised clinical trial of olaparib compared with placebo in people with newly diagnosed FIGO stage 3 or 4, BRCA mutation-positive advanced ovarian cancer after first-line platinum-based chemotherapy. The committee concluded that olaparib showed an impressive improvement in progression-free survival. The extent to which the progression-free survival benefit will translate into overall survival benefit is uncertain, but it is expected that treatment with olaparib will extend life. The clinical trial evidence as currently available does not show a significant difference in overall survival between olaparib and placebo, making estimates of cost effectiveness very uncertain. It was concluded that if olaparib increases the length of time people live it has the potential to be cost effective, but more evidence from the ongoing trial is needed to address the uncertainties. Therefore, it is recommended for use in the Cancer Drugs Fund, while further data are collected.